Singapore markets closed

Straits Times Index
3,384.29
+20.61(+0.61%)
Nikkei
27,509.46
+107.41(+0.39%)
Hang Seng
21,660.47
-297.89(-1.36%)
FTSE 100
7,901.80
+81.64(+1.04%)
BTC-USD
23,363.04
-16.80(-0.07%)
CMC Crypto 200
535.42
-1.43(-0.27%)

ADTX Jan 2024 1.000 call

OPR - OPR Delayed Price. Currency in USD

Add to watchlist

0.1500

0.0000

(0.00%)

As of 02:54PM EST. Market open.

Zacks
Is the Options Market Predicting a Spike in Aditx (ADTX) Stock?
Investors need to pay close attention to Aditx (ADTX) stock based on the movements in the options market lately.
Business Wire
Aditxt Forms Adimune, Inc. as a Wholly Owned Subsidiary with a Focus on Immune Modulation Therapies and Appoints Dr. Friedrich Kapp, Former President of the Therapeutic Business Unit at Schering AG, as its Chairman and CEO
RICHMOND, Va., January 03, 2023--Aditxt, Inc. (NASDAQ: ADTX) ("Aditxt" or the "Company"), a biotech innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system, today announces the formation of a U.S.-based subsidiary Adimune, Inc. ("Adimune™) and its plans towards submission of a Clinical Trial Application ("CTA") for its immunotherapeutic technology drug candidate, ADI™-100 ("ADI™-100" or "ADI™"). The CTA application will request a
Zacks
Implied Volatility Surging for Aditx Therapeutics (ADTX) Stock Options
Investors need to pay close attention to Aditx Therapeutics (ADTX) stock based on the movements in the options market lately.